ArticleRegenerative biomaterials2025
Matrix metalloproteinase-2 and pH-responsive drug eluting multilayer as intraocular lens coating to improve the posterior capsule opacification inhibition.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combating posterior capsular opacification: From conventional intraocular lens modifications to proactive defense via interface engineering.Materials today. Bio · 2026Review
- Photothermal and cascade ROS generative multilayer as intraocular lens surface coating for effective posterior capsular opacification inhibition.Regenerative biomaterials · 2026Article
- Biomimetic lung-targeting vehicle coupled with cryo-shocked leukocyte and inflammation-anchored liposome for drug delivery and anti-inflammation in treatment of acute pneumonia.Regenerative biomaterials · 2026Article
- Cataract: Surgery first - is there still room for basic research?Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraocular lens (IOL) is a crucial implant for cataract therapy. Posterior capsule opacification (PCO) is the most common postoperative complication after IOL implantation, which is the abnormal hyperplasia of the residual lens epithelial cells (LECs) after IOL implantation in cataract surgery. It is reported that the cellular microenvironment in the lens capsule changes after surgery, such as the elevated secretion of matrix metalloproteinases (MMPs) and a decrease in pH due to undesired cell proliferation. In this study, MMP-2 and pH-triggered drug delivery polysaccharide multilayer coating was designed and introduced onto the IOL surface for obtaining the cellular microenvironment-sensitive drug-eluting intraocular implant. The methacrylated heparin (HEP-MA) was synthesized and used to layer-by-layer self-assemble with the doxorubicin-loaded chitosan nanoparticles on the IOL surface. The matrix metalloproteinase-2 (MMP-2) sensitive peptide with cysteine contained in both ends (GCRD-GPQGIWGQ-DRCG) was then used to crosslink the polysaccharide multilayer via the Michael addition reaction between sulfhydryl group in cysteines and double bonds in methacrylate groups. The multilayer construction and subsequent cross-linking were validated through ultraviolet-visible spectrophotometer (UV-Vis) and Fourier transform infrared spectroscopy (FTIR). After modification, the IOL material surface becomes more hydrophilic while the optical properties were well maintained. The MMP-2 and pH-sensitive drug sustained-release coating were successfully obtained on the IOL surface via such design. The enzyme-triggered cell proliferation inhibition was realized in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.